# Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

> **NCT07361484** · PHASE3 · NOT_YET_RECRUITING · sponsor: **BeyondSpring Pharmaceuticals Inc.** · enrollment: 442 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Non-squamous Non-Small Cell Lung Cance

## Interventions

- **DRUG:** Plinabulin
- **DRUG:** Docetaxel
- **DRUG:** Placebo (matching plinabulin placebo)

## Key facts

- **NCT ID:** NCT07361484
- **Lead sponsor:** BeyondSpring Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2029-06-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 442 (ESTIMATED)
- **Last updated:** 2026-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07361484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07361484, "Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07361484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*